Characterization of inhibitory anti-Duffy binding protein II immunity: approach to Plasmodium vivax vaccine development in Thailand.

PloS One
Patchanee ChootongJohn H Adams

Abstract

Plasmodium vivax Duffy binding protein region II (DBPII) is an important vaccine candidate for antibody-mediated immunity against vivax malaria. A significant challenge for vaccine development of DBPII is its highly polymorphic nature that alters sensitivity to neutralizing antibody responses. Here, we aim to characterize naturally-acquired neutralizing antibodies against DBPII in individual Thai residents to give insight into P. vivax vaccine development in Thailand. Anti-DBPII IgG significantly increased in acute vivax infections compared to uninfected residents and naive controls. Antibody titers and functional anti-DBPII inhibition varied widely and there was no association between titer and inhibition activity. Most high titer plasmas had only a moderate to no functional inhibitory effect on DBP binding to erythrocytes, indicating the protective immunity against DBPII binding is strain specific. Only 5 of 54 samples were highly inhibitory against DBP erythrocyte-binding function. Previously identified target epitopes of inhibitory anti-DBPPII IgG (H1, H2 and H3) were localized to the dimer interface that forms the DARC binding pocket. Amino acid polymorphisms (monomorphic or dimorphic) in H1 and H3 protective epitopes chan...Continue Reading

References

Nov 1, 1992·Molecular and Biochemical Parasitology·J H AdamsL H Miller
Aug 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·J H AdamsL H Miller
Apr 1, 1986·The Journal of Infectious Diseases·M HoD A Warrell
Jan 1, 1982·Transactions of the Royal Society of Tropical Medicine and Hygiene·D H De SilvaP E Soyza
Apr 1, 1995·Annals of Tropical Medicine and Parasitology·J W Barnwell, M R Galinski
Oct 28, 1998·The American Journal of Tropical Medicine and Hygiene·P A MichonJ H Adams
Jun 27, 2001·The American Journal of Tropical Medicine and Hygiene·K MendisR Carter
Jul 10, 2001·The Korean Journal of Parasitology·W G KhoW C Chung
Sep 10, 2002·The Journal of Immunology : Official Journal of the American Association of Immunologists·Jia XainliChristopher L King
Apr 4, 2003·Molecular and Biochemical Parasitology·Jennifer Cole-Tobian, Christopher L King
Apr 22, 2003·Infection and Immunity·Jia XainliChristopher L King
Jul 2, 2003·The British Journal of Psychiatry : the Journal of Mental Science·Wolfgang Rutz
Jan 27, 2004·Education for Health : Change in Training & Practice·J J Guilbert
Apr 22, 2004·Trends in Parasitology·Jetsumon SattabongkotLiwang Cui
Jun 5, 2008·Proceedings of the National Academy of Sciences of the United States of America·Christopher L KingChetan E Chitnis
Jun 28, 2008·Malaria Journal·Panita GosiScott R Miller
Oct 14, 2008·Trends in Parasitology·James G BeesonChristian R Engwerda
Aug 7, 2010·PLoS Neglected Tropical Diseases·Carlos A GuerraSimon I Hay
Jul 12, 2011·Nature Structural & Molecular Biology·Joseph D BatchelorNiraj H Tolia
Aug 11, 2011·PloS One·Taís Nóbrega de SousaCristiana Ferreira Alves de Brito

❮ Previous
Next ❯

Citations

Sep 4, 2014·Memórias do Instituto Oswaldo Cruz·Taís Nóbrega de SousaLuzia Helena Carvalho
Dec 3, 2016·International Journal for Parasitology·Wai-Hong ThamJulian C Rayner
Apr 5, 2019·The Journal of Immunology : Official Journal of the American Association of Immunologists·Lenore L CariasChristopher L King
Mar 1, 2017·Frontiers in Immunology·Carolina LópezManuel A Patarroyo

❮ Previous
Next ❯

Methods Mentioned

BETA
ELISA
transfection

Software Mentioned

SPSS

Related Concepts

Related Feeds

Antimalarial Agents (ASM)

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

Antimalarial Agents

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.